Oramed Pharmaceuticals (ORMP) Liabilities and Shareholders Equity (2011 - 2026)

Oramed Pharmaceuticals has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $268.8 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 82.22% year-over-year to $268.8 million; the trailing twelve-month figure through Mar 2026 stood at $881.9 million (up 35.23% YoY), and the FY2025 full-year result was $230.9 million, up 48.68% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $268.8 million, up from $230.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $268.8 million in Q1 2026, with the low at $147.5 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $186.2 million across 5 years, with a median of $165.1 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 29.6% — and 2026, when it jumped 82.22%.
• Oramed Pharmaceuticals' Liabilities and Shareholders Equity stood at $161.6 million in 2022, then soared by 36.44% to $220.6 million in 2023, then dropped by 29.6% to $155.3 million in 2024, then soared by 48.68% to $230.9 million in 2025, then climbed by 16.45% to $268.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $268.8 million (Q1 2026), $230.9 million (Q4 2025), and $220.5 million (Q3 2025), per Business Quant data.